CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study

Recruiting in Palo Alto (17 mi)

Overseen by Amar Kishan

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Jonsson Comprehensive Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This phase III trial studies compares CT-guided stereotactic body radiation therapy and MRI-guided stereotactic body radiation therapy (SBRT) in treating prostate cancer. Image-guided SBRT is a standard treatment for prostate cancer, which combines imaging of the cancer within the body with the delivery of therapeutic radiation doses produced on a linear accelerator machine. Imaging modalities for image-guided SBRT can be either computed tomography imaging (CT), magnetic resonance imaging (MRI), or a combination of the two. This research is being done to help determine whether there are benefits to MRI-guidance over CT-guidance in patients who are receiving the same radiation dose by SBRT to treat prostate cancer.

Eligibility Criteria

Inclusion Criteria

High-risk: technetium bone scan, CT abdomen/pelvis if MSKCC nomogram predicts >10% probability of lymph node involvement

Histologically confirmed, clinical localized adenocarcinoma of the prostate

No evidence of disease beyond the prostate and/or seminal vesicles (i.e., no suspicious pelvic lymph nodes or presence of metastatic disease outside the pelvis)

Treatment Details

Interventions

• CT-guided Stereotactic Body Radiation Therapy (Radiation Therapy)
• MRI-guided Stereotactic Body Radiation Therapy (Radiation Therapy)

Participant Groups

Group I: Group II (MRI-SBRT) Experimental Treatment 2 Interventions

Patients undergo 5 fractions of MRI-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.

Group II: Group I (CT-SBRT) Experimental Treatment 2 Interventions

Patients undergo 5 fractions of CT-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

UCLA / Jonsson Comprehensive Cancer Center Los Angeles, CA

Who Is Running the Clinical Trial?

Jonsson Comprehensive Cancer Center Lead Sponsor

References